Rivaroxaban

From Citizendium
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Rivaroxaban.png
rivaroxaban
IUPAC name: (S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide
Synonyms: Xarelto
Formula: C19H18ClN3O5S

 Uses: prevention of deep vein thrombosis

 Properties: anticoagulant

 Hazards: see side effects & drug interactions

Mass (g/mol): CAS #:
435.88132 366789-02-8



For more information, see: Coagulation.

In medicine, rivaroxaban is an anticoagulant that inhibits factor Xa.[1] Like warfarin, rivaroxaban is given orgally, but unlike warfarin rivaroxaban is administered in fixed doses without the need for coagulation monitoring.


History

Rivaroxaban was approved for use by the European Medicines Agency in 2009 "to prevent venous thromboembolism (VTE, the formation of clots in the veins) in adults who are undergoing surgery to replace a hip or knee."[2]

Rivaroxaban was approved by the Food and Drug Administration in the United States 7/2011.[3] for "the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery."

Pharmacology

Administration

Rivaroxaban is given orally

Distribution

Metabolism

Excretion

Toxicity

Clinical uses

Deep venous thrombosis

Rivaroxaban can treat symptomatic embolism and thrombosis of the deep leg veins.[4]

Rivaroxaban can prevent embolism and thrombosis during perioperative care according to randomized controlled trials with two weeks of therapy after knee arthoplasty[5] or 5 weeks of therapy after hip arthroplasty.[6][7]

External links

The most up-to-date information about Rivaroxaban and other drugs can be found at the following sites.


References

  1. Anonymous (2023), Rivaroxaban (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Anonymous (2009) EPARs for authorised medicinal products for human use European Medicines Agency
  3. Anonymous (2011) FDA approves Xarelto to reduce risk of blood clots after hip, knee replacements
  4. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al. (2010). "Oral rivaroxaban for symptomatic venous thromboembolism.". N Engl J Med 363 (26): 2499-510. DOI:10.1056/NEJMoa1007903. PMID 21128814. Research Blogging.
  5. Lassen MR, Ageno W, Borris LC, et al (June 2008). "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty". The New England journal of medicine 358 (26): 2776–86. DOI:10.1056/NEJMoa076016. PMID 18579812. Research Blogging.
  6. Eriksson BI, Borris LC, Friedman RJ, et al (June 2008). "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty". The New England journal of medicine 358 (26): 2765–75. DOI:10.1056/NEJMoa0800374. PMID 18579811. Research Blogging.
  7. Kakkar AK, Brenner B, Dahl OE, et al (July 2008). "Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial". Lancet 372 (9632): 31–9. DOI:10.1016/S0140-6736(08)60880-6. PMID 18582928. Research Blogging.